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Abstract
Over the past 30 years, it has been demonstrated that 
removal of white blood cells from blood components 
is effective in preventing some adverse reactions 
such as febrile non-haemolytic transfusion reactions, 
immunisation against human leucocyte antigens 
and human platelet antigens, and transmission of 
cytomegalovirus. In this review we discuss indications 
for leucoreduction and classify them into three 
categories: evidence-based indications for which the 
clinical efficacy is proven, indications based on the 
analysis of observational clinical studies with very 
consistent results and indications for which the clinical 
efficacy is partial or unproven.
Keywords: blood component transfusion, leucocyte 
reduction procedures, leucocyte reduction filtration, 
cost effectiveness, transfusion reactions.
Introduction
Leucocytes and leucocyte-derived cytokines are 
associated with several adverse outcomes of transfusion 
therapy1. Leucoreduction (LR) is the reduction of white 
blood cell (WBC) concentration in blood components, 
namely red blood cell concentrates (RBC), platelet 
concentrates (PC) and plasma obtained from the 
fractionation of whole blood or apheresis. There are 
many methods of LR but, currently, this process may 
be performed using selective LR filters, which enable 
less than 1×106 residual WBC to be obtained in a RBC 
or PC unit.
Over the past 30 years, it has been demonstrated 
that LR can reduce some adverse reactions due to blood 
component transfusion such as febrile non-haemolytic 
transfusion reactions (FNHTR), immunisation against 
human leucocyte antigens (HLA) and human platelet 
antigens (HPA), which may cause refractoriness to 
platelet transfusion, and transmission of cytomegalovirus 
(CMV)2,3. Furthermore, LR improves the clinical outcome, 
in terms of reducing mortality and post-operative 
infections, in patients undergoing cardiac surgery2,3. 
As  f a r  a s  conce rns  t r ans fus ion- re l a t ed 
immunomodulation, risk of multi-organ failure and 
mortality in surgical patients, as well as the prevention 
of transmission of some viruses and prions, the possible 
benefits associated with LR are supported by less strong 
(or only experimental) evidence4,5.
In this article, which deals with the role and cost-
effectiveness of LR in contributing to the safety of 
blood transfusion, we review the indications for LR and 
arbitrarily classify them into three categories: evidence-
based indications for which the clinical efficacy has 
been proven (based on results from randomised clinical 
trials [RCT] or meta-analyses), indications based on 
the analysis of observational clinical studies with very 
consistent results6 and indications for which the clinical 
efficacy is partial or unproven (based on observational 
studies with less consistent results, cohort studies or 
case series). 
Evidence-based indications for which the 
clinical efficacy has been proven
Prevention of immunisation against human leucocyte 
antigens and human platelet antigens, and platelet 
refractoriness
Platelet refractoriness may be due to several 
mechanisms:  non- immune condi t ions  such 
as splenomegaly, fever and/or sepsis, antibiotics, 
disseminated intravascular coagulation and complement-
mediated destruction, as well as immune reactions such 
as alloimmunisation caused by previous pregnancies, 
transfusion or organ transplantation7. 
HLA immunisation is a complication of transfusion 
therapy which can lead to refractoriness to platelet 
transfusion, especially in onco-haematological 
patients. From 20 to 60% of these patients may 
develop this condition due to multiple transfusions8. 
Alloimmunisation occurs most commonly against HLA 
class I antigens, although HPA may also be involved9. 
The risk of alloimmunisation against HLA antigens 
and the consequent risk of platelet refractoriness were 
first assessed in the 1990s10-16. In 1988, an early study 
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by Brand and co-authors showed that leucocyte-depleted 
RBC and multiple random donor platelet transfusions 
were very unlikely to induce primary immunisation to 
HLA and non-HLA platelet-reactive antigens10. Three years 
later, in a randomised trial, Oksanen et al. administered 
WBC-reduced PC and RBC to adult patients with acute 
leukaemia and non WBC-reduced blood components 
to control patients11. Patients in the former group 
did not develop platelet refractoriness whereas one 
patient in the control group became refractory and two 
developed transient HLA antibodies. Van Marwijk 
Kooy et al. conducted a prospective RCT to assess 
the role of LR in preventing HLA immunisation and 
platelet refractoriness12. Adult patients with acute 
leukaemia were transfused with PC prepared either by 
centrifugation (control group) or filtration (study group). 
Both groups received RBC that had been filtered, after 
buffy coat removal. Refractoriness occurred in 46% of 
the evaluable control patients and in only 11% of the 
study subjects (p<0.005). De novo anti-HLA antibodies 
were detected in 42% of the control patients and in 
only 7% of the patients who received filtered PC. In 
1994, Williamson et al. carried out a RCT comparing 
patients who received either non-leucoreduced or 
bedside-filtered blood components13. Interestingly, 
both groups showed similar rates of alloimmunisation 
(37% among patients who received non-filtered blood 
components and 21% among patients transfused with 
bedside-filtered blood components; p=0.07). According 
to the authors, the efficacy of bedside filtration could 
have been hampered by intrinsic biological limitations, 
namely the possible immunogenic potential of stored 
blood component supernatants; in addition, the removal 
of WBC upon storage just before transfusion might 
not be the most effective way to prevent transfusion of 
WBC-derived cytokines.
In 1997, the multicentre Trial to Reduce 
Alloimmunization to Platelets (TRAP) clearly showed 
significant differences between patients transfused with 
filtered PC (F-PC), ultraviolet B-irradiated pooled PC 
(UVB-PC) or filtered apheresis platelets (F-AP) and 
controls who received unmodified, pooled PC14. Out of 
530 patients, 13% of those in the control group became 
refractory to platelet transfusions, as compared with 
3% in the F-PC group, 5% in the UVB-PC group, and 
4% in the F-AP group (p<0.03 for each treated group 
as compared with controls). 
Later, Vamvakas published a meta-analysis15, which 
included the TRAP study data, and demonstrated a 
significant reduction of the cumulative relative risk of 
alloimmunisation against HLA antigens (−68%, 95% 
confidence interval [CI]: 0.18-0.56) resulting from the 
use of leucoreduced blood components. Both these 
studies also showed that naïve patients transfused 
with leucoreduced blood components had a lower 
risk of developing refractoriness to PC transfusion in 
comparison with patients with a high risk of previous 
immunisation (i.e. previous pregnancies)14,15. 
In 2005, Slichter et al. analysed the TRAP database 
to evaluate patient- and product-related characteristics 
that could influence post-transfusion platelet response 
in thrombocytopenic patients16. After evaluating factors 
affecting post-transfusion platelet increments, platelet 
refractoriness, and platelet transfusion intervals, they 
clearly showed that increasing the dose of platelets 
transfused or transfusing filtered apheresis platelets had 
a key role in reducing platelet refractoriness.
Recently, in 2014, Jackman et al. published an 
interesting study on the role of LR and UV treatment 
of PC in the prevention of immunisation frequency, 
duration, and magnitude (i.e. "qualitative HLA 
determination followed by evaluation of normalised 
background ratios for each of eight multi-antigen 
beads; significance was assessed for a normalised 
background ratio >10.8 for class I HLA antibodies 
and 6.9 for class II") of HLA antibody responses in 
transfusion recipients17. After selecting 321 patients from 
four different studies14,18-21 (namely, 190 patients from 
TRAP14, 72 from a microchimerism study in trauma 
patients18, 37 patients from the Transfusion-Transmitted 
Viruses Study [TTVS]19,20, and 20 from the Transfusion-
Related Infections Prospective Study [TRIPS])21, they 
showed different immunisation behaviours. Interestingly, 
subjects who received leucoreduced or UV-treated 
blood products were less likely to generate class I HLA 
antibodies and patients who received leucoreduced 
blood were also less likely to generate class II HLA 
antibodies. Among those who received non-leucoreduced 
PC, 55% developed class I HLA antibodies and 51% 
developed class II HLA antibodies in comparison with 
28% (class I) and 15% (class II) among those who 
received leucoreduced blood and 36% (class I) and 
54% (class II) among those who received UV-treated 
blood, respectively. In addition, among alloimmunised 
subjects, LR resulted in a significant 2-fold reduction 
of the magnitude of class I HLA antibodies, and UV 
treatment resulted in a significant 3-fold reduction of the 
magnitude of class II HLA antibodies. The persistence of 
class I HLA antibodies was shorter with both treatments. 
Therefore, LR and UV treatment of blood products not 
only reduced the incidence of HLA antibody production, 
but also caused lower and more transient HLA antibody 
levels among sensitised transfusion recipients. 
According to the review of the algorithms to 
recognise and manage HPA or combined HPA and HLA 
antibodies performed by Vassallo in 200922, after a poor 
response to platelet transfusions in thrombocytopenic 
patients (defined as a corrected count increment <5,000 
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or inadequate platelet count increment), the possible 
strategies included transfusion of "fresh" (less than 
48 hours old) ABO-compatible PC, HLA- and/or 
HPA-selected single donor platelets or pre-transfusion 
cross-matching. Furthermore, a recent guidance 
document on platelet transfusion for patients with 
hypoproliferative thrombocytopenia by Nahirniak and 
the members of the International Collaboration for 
Transfusion Medicine Guidelines recommends that 
"patients with hypoproliferative thrombocytopenia 
who are refractory to platelet transfusions and have 
class I HLA antibodies should probably receive 
class I HLA-selected or crossmatch-selected platelet 
transfusion to increase the platelet count" while 
"patients with hypoproliferative thrombocytopenia 
who are refractory to platelet transfusions and have 
HPA antibodies should probably receive HPA-selected 
or crossmatch-selected platelet transfusion to increase 
the platelet count"23. 
In conclusion, LR is effective (especially in 
high-risk patients) in preventing platelet alloimmune 
refractoriness, namely the persistent suboptimal platelet 
count increment following a platelet transfusion, 
arising from exposure to contaminating WBC in PC 
(class I HLA antigens) or less commonly, to platelet-
specific antigens. This implies that, in patients with 
hypoproliferative thrombocytopenia, when leucoreduced 
platelet products are available, WBC-depleted platelets 
should be used as equivalent products to apheresis 
platelets23.
Indications based on the analysis of observational 
clinical studies with very consistent results
Prevention of cytomegalovirus infection 
CMV is one of the herpes viruses responsible for a 
common and harmless infection in immunocompetent 
subjects with a seroprevalence in adults ranging from 
40 to 100%24. 
CMV infection in immunocompetent individuals 
is often asymptomatic (40-90%) or has a mild 
mononucleosis-like course, but it may be a life-
threatening condition in some categories of subjects 
such as foetuses, premature infants, patients infected by 
human immunodeficiency virus, onco-haematological 
patients and CMV-seronegative candidates for solid 
organ or haematopoietic stem cell transplantation25. 
Infection in immunocompromised individuals may be 
associated with considerable mortality and morbidity 
such as pneumonitis, gastroenteritis and retinitis. 
Transfusion-transmitted CMV infections have 
traditionally been explained by transmission of latently 
infected WBC. The issue of CMV transmission by blood 
products was first addressed in 1984, well before the 
introduction of LR26.
Some early studies demonstrated that both 
policies, namely the use of CMV-seronegative blood 
components and LR, may be able to reduce CMV 
infection significantly in high-risk patients. However, 
controversies concerning "the gold standard" practice 
(only LR, only CMV-donor status, and LR plus CMV-
donor status) are still ongoing27-29. 
In 2001, a panel of experts from the CMV Consensus 
Conference held in Canada, although agreeing that 
CMV infection could be prevented both by selecting 
CMV-negative blood donors and by transfusing 
leucoreduced blood components and that quality 
control of LR was excellent, issued recommendations 
for the use of CMV-negative blood products for high-
risk populations as no consensus was reached on the 
question of whether serological CMV testing should 
be abandoned or not, given that universal LR had been 
recently introduced in that country30. 
In 2005, Vamvakas published a meta-analysis 
demonstrating that CMV-seronegative blood components 
are more efficacious than LR in preventing transfusion-
transmitted infection31. This meta-analysis evaluated 829 
patients (in 11 studies) transfused with CMV-negative 
blood components and 878 patients (in 12 studies) 
transfused with leucoreduced blood components. 
CMV infection was detected in 1.45% of the patients 
transfused with CMV-negative blood components 
compared to 2.73% of the patients transfused with 
leucoreduced blood components. 
On the other hand, several retrospective studies 
demonstrated the efficacy of LR in preventing CMV 
transmission in transplanted patients. In 2005, Narvios 
et al. evaluated CMV infection in 72 CMV-negative 
allogeneic haematopoietic transplant patients who 
received bedside leucoreduced blood components32: 11 
patients seroconverted; one patient was positive for CMV 
antigenaemia 4 months after transplantation, but did not 
have CMV infection; two out of 61 patients who did not 
seroconvert were CMV antigen-positive and did not have 
CMV infection. 
In 2012, Nash et al. reported their experience 
with 100 CMV-negative patients who underwent 
allogeneic hematopoietic stem cell transplantation 
and received leucoreduced but mainly CMV-untested 
blood components33. In total, 6,465 units were 
transfused without any case of clinical CMV disease 
or positive CMV nucleic acid testing (NAT) after 
transplantation. Only two cases of seroconversion 
were reported and were attributed to passive antibody 
transmission. A recent retrospective analysis carried 
out in haematopoietic transplant patients confirmed 
the efficacy of universal LR in preventing transfusion-
transmitted CMV infection34. In this study, recipients of 
leucoreduced or CMV-negative blood components did 
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not show a significant difference in terms of infection 
(p=0.6244).
Although there is no general agreement, it is 
acknowledged that the use of either seronegative 
or leucodepleted blood components consistently 
reduces (93.1% and 92.3%, respectively)31 the risk of 
transmitting CMV35,36. Nevertheless, persistence of 
CMV DNA after WBC removal explains the uncommon 
CMV infection in recipients of universally leucoreduced 
blood components37 and fuels the ongoing debate on the 
relative safety of these two approaches as prevention 
strategies for transfusion-transmitted CMV. 
In this scenario, a third, different strategy, namely 
transfusion of leucodepleted blood components from 
seropositive donors with seroconversion more than 1 
year previously, in whom CMV DNA is rarely detectable 
or absent38,39, has been proposed based on the rationale 
that this would prevent the transfusion of blood from 
donors with acute infection and high viral loads39,40. On 
this basis, in addition to LR, provision of seronegative 
blood products, provision of long-term seropositive 
blood donors, and provision of CMV DNA-negative 
blood products were even proposed as alternative 
strategies41. 
At present, there is a significant variability in local 
policies both at the hospital level and the blood operator 
level, nationally and internationally. While many 
centres use CMV-safe products (i.e. containing less 
than <1,5×106 residual leucocytes per unit) for high-risk 
adult transplant patients, many continue to order CMV-
seronegative leucoreduced blood components for high-
risk neonates, intrauterine transfusions and pregnant 
patients36. In some countries, such as Canada, the 
national guidelines allow the combined policy only for 
high-risk patients, such as candidates for transplants42. In 
the USA, a recent survey of current practices found that 
65% of the interviewed institutions evaluated selection 
of CMV-negative blood donors and leucoreduced 
blood components similarly safe43. On the other hand, 
the 1999 Swiss clinical practice recommendations 
considered seronegative units to be the gold standard 
for the prevention of transfusion-transmitted CMV, 
and concluded that leucoreduced units had not yet 
been proven equivalent44. According to the 2015 Italian 
recommendations for transfusion therapy in neonatology 
and to the 2009 guidance document for the transfusion 
of red blood cells45,46, these two strategies are both able 
to effectively prevent transfusion-transmitted CMV. In 
fact, both leucoreduced and CMV-seronegative units 
have an equal and very low residual risk of transmitting 
CMV. CMV-seronegative products are able to transmit 
CMV, if donated during the 6- to 8-week serological 
window period after the infection while leucoreduced 
units can transmit this virus because of the partial failure 
to remove WBC from a very limited number of units 
(0-2%). Naturally, as window-phase seroconversion is 
associated with cell-free CMV in the plasma, which 
is not removed by LR, these two strategies are not 
additive47,48. Interestingly, despite the evidence that the 
efficacy of these two methods in preventing transfusion-
transmitted CMV may not be additive, an ongoing 
prospective birth cohort study, aimed at estimating the 
incidence of transfusion-transmitted CMV infection 
in low-birth weight neonates (≤1,500 g) who receive 
CMV-seronegative plus leucoreduced blood components 
(NCT00907686, available at www.clinicaltrials.gov), is 
being carried out49. The primary outcome of this study is 
to evaluate the incidence of CMV infection in patients 
who receive a combination of CMV-seronegative 
and leucoreduced blood components. The secondary 
outcome is to detect CMV-DNA and/or elevated residual 
WBC counts (due to WBC filter failures) in transfused 
blood components and to correlate these results with 
episodes of breakthrough CMV infection in the study 
population. 
At present, internationally shared guidelines on the 
prevention of transfusion-transmitted CMV in high-risk 
patients do not exist and a recent survey "highlights that 
while many centres are becoming more comfortable using 
CMV-safe products for high-risk adult transplant patients, 
many continue to order CMV-seronegative leucoreduced 
products for high-risk neonates, intrauterine transfusions 
and pregnant patients"36. In addition, most centres 
continue to have a dual inventory and provide both 
leucoreduced and CMV sero-negative products to 
selected high-risk populations.
There is, therefore, a clear need for international 
collaborative studies comparing rates of transfusion-
transmitted CMV infection following use of CMV-safe 
and/or CMV-negative products, which will help to 
collect the data necessary to develop the aforementioned 
international guidelines on CMV risk management. 
However, as these studies would be impractical 
due to the large numbers of patients needed to produce 
convincing results, the improved performance of 
WBC filters and the currently available literature 
provide adequate evidence regarding the equivalence 
of using leucoreduced products alone. In addition, a 
recent estimate of the residual risk associated with 
leucoreduced-only blood components carried out 
in Australia showed that, notably, this risk is below 
the threshold of 1 in 1 million, generally considered 
negligible50.
Febrile non-haemolytic transfusion reactions
FNHTR are defined as rises in temperature greater 
than or equal to 1 °C that cannot be explained by the 
patients' clinical picture. Such reactions are often 
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associated with other inflammatory symptoms such as 
chills, cold, rigors, and discomfort. Nausea, vomiting, 
and headache may also be present. Generally, FNHTR 
occur during a transfusion or within 4 to 6 hours after 
its conclusion51. 
Several mechanisms have been proposed to explain 
the role of donor leucocytes in the pathogenesis of fever 
in transfusion recipients. In particular, three of the above-
mentioned mechanisms are worth mentioning: infusion 
of passenger lymphocytes into recipients alloimmunised 
against leucocytes and platelets; infusion of pyrogenic 
cytokines (interleukin-6 [IL-6], interleukin-8 [IL-8], 
tumour necrosis factor-alpha [TNF-α], interleukin-1beta 
[IL-1β], and CD40L) and other inflammatory mediators 
(activated complement proteins and neutrophil-priming 
lipids) that accumulate during storage; and infusion 
of blood components contaminated with bacteria or 
bacterial products1,52,53. All these three mechanisms cause 
fever through the release of inflammatory cytokines. 
In 2004, three retrospective studies demonstrated the 
efficacy of LR in significantly lowering the incidence of 
FNHTR after the transfusion of pre-storage leucoreduced 
PC and RBC54-56. Paglino et al. assessed a total of 
145,369 RBC and 137,982 PC transfused in 8 years 
and found a significant decrease of the relative FNHTR 
rate: 47.1% for RBC (from 0.34 to 0.18%; p<0.0001) 
and 93.1% for PC (from 2.18 to 0.15%; p<0.0001)54. 
King et al. reported a reduction of FNHTR events from 
0.37% (n=60) to 0.19% (n=37; p=0.0008) after 16,246 
and 19,916 RBC transfusions, respectively55. Yazer 
et al. confirmed the significant reduction of FNHTR 
(from 0.37% to 0.19%, p=0.001) after 72,949 RBC 
transfusions and 50,555 PC transfusions, respectively56. 
In 2012, Wang et al. in a retrospective analysis of 
70,015 platelet doses assessed the incidence of FNHTR 
associated with transfusions of prestorage-leucoreduced 
pooled platelets, post-storage-leucoreduced pooled 
platelets, non-leucoreduced pooled platelets, and 
apheresis single-donor platelets57. There were 152 
(0.22%) FNHTR: the rate of reactions to apheresis 
single-donor platelets, prestorage-leucoreduced pooled 
platelets, post-storage-leucoreduced pooled platelets, 
and non-leucoreduced pooled platelets were 0.07%, 
0.16%, 0.30%, and 0.20%, respectively. The difference 
in the percentage of FHNTR between non-leucoreduced 
pooled platelets and other types of leucoreduced platelets 
was statistically significant only in comparison with 
apheresis single-donor platelets (p=0.008) and post-
storage-leucoreduced pooled platelets (p=0.045). This 
study, therefore, confirmed previous data showing that 
the timing of LR during storage probably influences 
the amount of accumulated cytokines in the transfused 
PC and has a key role in the pathogenesis of FNHTR.
In 2002, a multicentre RCT was carried out by 
Heddle et al. in adults with haematological malignancies 
randomised to receive one of three types of platelet 
products58: (i) PC from which the plasma supernatant 
had been removed and a platelet storage solution had 
been added; (ii) whole blood-derived PC leucoreduced 
prestorage by filtration; and (iii) prestorage leucoreduced 
apheresis PC. This study was designed to determine 
whether prestorage LR was more effective than plasma 
removal in preventing platelet-associated transfusion 
reactions and to compare the effectiveness of two 
methods of prestorage LR for preventing reactions. 
Unfortunately, due to the low power of the study, a 
significant difference in the frequency of reactions 
associated with plasma-depleted (21.3%) and prestorage 
leucoreduced (12.3%) PC was not shown. In addition, 
no difference in the frequency of reactions to the two 
types of prestorage leucoreduced PC was detected and 
the frequency of severe reactions to these PC was limited 
to only 1 to 2% of transfusions.
Although it is the most frequent adverse effect 
following the transfusion of RBC and PC, FNHTR are not 
typically life-threatening and LR effectively reduces the 
frequency of FNHTR during PC and RBC transfusions. 
However, despite its relative high frequency, FNHTR is 
definitively quite rare and a RCT aimed at comparing 
the incidence of this adverse outcome in study subjects 
(transfused with leucoreduced blood components) 
and controls (transfused with non-leucoreduced blood 
components) would require a huge number of patients5. 
For this reason, the currently available evidence of 
clinical benefits of LR stems mainly from "before-
and-after" universal LR retrospective observational 
studies rather than RCT. Although subjects included 
in observational studies more closely resemble those 
patients we come across in daily clinical practice, results 
from such studies should be confirmed by controlled 
clinical trials in order to further strengthen their very 
consistent results.
Indications for which the clinical efficacy is 
partial or unproven
Transfusion immunomodulation
Experimental evidence suggests that RBC transfusion 
may have an effect on the immune system causing a 
dysregulation of innate immunity and inflammatory 
processes with a consequent increased susceptibility 
to infections, as well as down-regulation of cellular 
immunity (T cells and NK cells). This may also have 
effects on immune status in the case of neoplasia and may 
cause hyper-activation of B cells during alloimmunisation 
phenomena59-63. In addition to cellular and cytokine 
production, other mechanisms may still modulate 
immune response in recipients. RBC units also contain 
non-polar lipids and a mixture of pro-inflammatory 
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lysophosphatidylcholines, which modulate the activity of 
NK and T cells, act as an NK-cell chemoattractant, induce 
dendritic cell maturation and stimulate the production of 
pro-inflammatory cytokines; eicosanoids (prostaglandins 
and thromboxanes) can also accumulate in RBC64-68. 
All these elements are now widely recognised as key 
players in transfusion-related immunomodulation, which 
is strongly associated with an increased risk of bacterial 
infection, promotion of cancer growth, multi-organ 
failure, and increased mortality in oncological patients. 
In the last 10 to 15 years, the results of several 
observational studies and RCT dealing with the role 
of LR in preventing post-operative infections have 
been published. In 2002, Vamvakas performed a meta-
analysis of eight heterogeneous RCT that investigated 
the relationship between the use of non-leucoreduced 
blood components and post-operative infections69. All 
these trials included patients randomised to receive 
leucoreduced or non-leucoreduced red cell concentrates 
or whole blood. Unfortunately, information about 
platelet or plasma transfusion was not reported. This 
analysis led to the conclusion that LR did not provide a 
significant benefit to the patients, in terms of infectious 
complications and mortality. 
In contrast, two other meta-analyses showed different 
results. Fergusson et al.2 and Blumberg et al.3 integrated 
the results of all RCT published or reported up to 2002 
and showed a decrease in the risk of post-operative 
infections attributable to LR. Fergusson et al. showed 
a summary risk ratio (RR) of 0.60 (95% CI: 0.38-0.93) 
in transfused patients2; the reduction of post-operative 
infections was more consistent in cardiac surgery (RR: 
0.77; 95% CI: 0.61-0.97). Blumberg et al.3 confirmed 
the statistically significant reduction of post-operative 
infections (odds ratio, 0.522; 95% CI: 0.332-0.821; 
p=0.005) and mortality in cardiac surgery whereas LR 
was devoid of effects in other surgical settings70-72.
On the other hand, in cardiac surgery, LR had no 
effects on the total amount of blood lost, the total number 
of RBC transfused73, or alloimmunisation reactions74,75. 
Moreover, LR has no impact on other outcomes such 
as 30-day mortality and post-operative comorbidity, as 
well as incidence of pneumonia and need for mechanical 
ventilation76. 
In 2007, Vamvakas addressed the reasons why 
meta-analyses of RCT on the association between 
non-leucoreduced allogeneic blood transfusion and 
post-operative infection produced discordant results77. 
He pointed out that the reasons for the aforementioned 
discordant results were probably due to researchers 
who did or did not investigate medical sources of 
heterogeneity and did or did not include the most recent 
RCT. Intention-to-treat and as-treated comparisons 
produced concordant results. 
In a similar way, transfusion of leucoreduced blood 
components in oncological patients resulted in contrasting 
data. An early Danish trial was carried out between 1992 
and 1995 on 589 colorectal cancer patients, including 
142 who received buffy-coat-depleted RBC, 118 who 
received leucoreduced units, and 329 who did not receive 
any type of blood components. Although it showed that 
patients transfused with leucodepleted RBC had fewer 
post-operative infectious complications than patients 
transfused with buffy-coat-depleted units, long-term 
outcome data were lacking78. In 2005, Jensen et al. 
published the results of a 7-year follow-up of the above-
mentioned patients and showed that recipients of buffy-
coat-depleted or leucoreduced RBC had worse outcome 
(7-year survival) than non-transfused patients79. In 2011, 
the cause-specific mortality in the aforementioned patients 
was analysed by Mortesen et al. in a post-trial 15-year 
follow-up study. This confirmed that patients who were 
not transfused during surgery had a better prognosis than 
transfused patients80. In fact, according to the authors, both 
recipients of leucoreduced RBC and recipients of buffy-
coat-depleted RBC had decreased long-term survival 
due to cardiovascular disease, although results were not 
statistically s gnificant different in the latter group.
In 2007, Skanberg et al. randomised 642 patients 
with colon cancer to receive leucoreduced or buffy-
coat-depleted RBC and showed that the study patients 
had better outcomes (in terms of length of hospital 
stay [<20 days] and need for respiratory support), but 
no improvement in overall survival due to leucocyte 
depletion of blood products after 6 years of follow-up81. 
In the same way, hospital stay was shorter and survival 
significantly increased in non-transfused patients 
compared to transfused patients. Koch et al. also showed 
that LR is associated with a poor post-operative course82. 
These studies confirmed that patients do not benefit 
from liberal transfusion practices and, similar to 
recent data, suggest that a more conservative approach 
(haemoglobin transfusion trigger <7 g/dL) can lead to 
reduced mortality and morbidity also in critically ill or 
bleeding patients83,84. 
In conclusion, the available evidence from clinical 
trials is not uniform and does not confirm the experimental 
evidence suggesting an immunosuppressive effect of 
blood transfusion. Statistically significant reductions of 
post-operative infections and mortality were shown in 
cardiac surgery. As far as other settings are concerned, 
the clinical effect of LR is probably smaller than 
detectable by trials and future studies might be needed 
to address the issue properly.
Prevention of other infections 
Currently, various approaches, such as strict donor 
selection criteria, as well as serological and molecular 
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screening tests, are used to avoid transfusion-transmitted 
infections. Notwithstanding this multi-step approach, 
infections still remain a challenge in transfusion medicine. 
Bacterial contamination of blood components occurs 
mainly at the time of venepuncture, due to inadequate 
skin preparation or asymptomatic bacteraemia in the 
donor. Although a consistent reduction of the risk of 
bacterial contamination of blood components is obtained 
through the diversion of the first part of the donation of 
blood and blood components85, LR may be an additional 
effective tool in preventing transmission of bacteria 
through blood components86. Andreu et al. confirmed 
this by analysing bacterial infection rates before and 
after the universal implementation of LR in France87: 
bacterial sepsis and FNHTR were the only events that 
were significantly reduced (p<0.001) from 3.8% to 1.7% 
and from 32.9% to 25.8%, respectively. Data about the 
prevention of viral infections, such as those caused by 
Epstein-Barr virus (EBV) and human T-lymphotropic 
virus (HTLV/1-2), have also been reported. LR may 
eliminate the need to screen blood for EBV for at-risk 
patients by reducing the viral load88,89. As far as concerns 
HTLV/1-2, three policies may be implemented90: (i) 
in developed non-endemic countries that have started 
universal control of donated blood and universal 
leucodepletion, the current very low observed incidence 
and prevalence among blood donors (reflecting a very 
low estimated risk of an HTLV-1 positive donation 
entering the blood supply) should prompt further 
review of the transmission risk and a possible change 
of the prevention strategy. The systematic screening 
of all donations should be questioned (and possibly 
interrupted, if already in use) after accurate evaluation of 
the residual HTLV transfusion risk, while leucodepletion 
of cellular blood products should be maintained or 
implemented if not in place. (ii) In developed countries 
with areas of high endemicity, the suppression of anti-
HTLV screening is not recommended but testing should 
be combined with leucodepletion until the efficiency of 
the latter procedure in preventing HTLV transmission 
is unequivocally proven. (iii) In developing countries 
in which HTLV is endemic and the residual risk of 
transfusion-transmitted infection is greater, given the 
high cost of universal testing and leucodepletion, more 
cost-effective strategies for blood donation screening 
need to be defined and assessed such as look-back 
studies aimed at infected-donor deferral and continued 
haemovigilance monitoring.
The transmission of variant Creutzfeld-Jakob disease 
(vCJD) from blood components is possible, since 
prions may be transmitted through buffy coat91. It is 
also possible to reduce vCJD transmission through LR 
filters92-94. Two experimental studies performed in animal 
models evaluated filter performance in preventing prions 
transmission. In 2011, McCutcheon et al. demonstrated, 
in a sheep model of vCJD, that standard LR filters 
are not able to reduce the level of prion proteins95. In 
contrast, 1 year later, Lacroux et al. demonstrated that 
prion transmission through blood components might 
be avoided using last-generation filters developed for 
prion proteins96. This opened up new possibilities for 
LR in countries in which the risk of transmission of 
vCJD through blood components is intermediate-high. 
However, as blood risk assessment in transmissible 
spongiform encephalopathy animal models suggests 
that infection is at least distributed among WBC and 
plasma97, LR can only partially remove prion-associated 
blood infectivity92. Therefore, in the last few years, 
complementary methods to actively secure blood 
transfusion further reducing the blood-borne risk of 
vCJD transmission were developed98-100. Data obtained 
from the evaluation of filter performances are presented 
in Table I. Recently, Cardone et al. demonstrated that 
it is possible to obtain a 100-fold reduction in blood 
components inoculated with scrapie-infected hamster 
brain homogenates by using affinity prion reduction 
filters101. In addition, further very promising results 
were added to the available experimental evidence on 
the potential of LR in preventing blood-borne vCJD 
by an ongoing study (after 5 to 6 years of progress) on 
prion blood removal performances of the P-Capt filter in 
macaques, an extremely relevant model for human prion 
diseases97. This study evaluated resin affinity-based 
prion removal filters designed for human transfusion. 
In conclusion, the only evidence, albeit very 
promising, on the effectiveness of LR in the prevention 
of the transmission of vCJD through transfusion of 
blood components is currently based on (robust) data 
from experimental studies carried out in animal models. 
Transfusion-associated acute lung injury and 
transfusion-associated Graft-versus-Host disease 
Transfusion-associated acute lung injury (TRALI) 
and transfusion-associated Graft-versus-Host disease 
(TA-GVHD) are life-threatening transfusion reactions 
that may involve leucocytes. However, the clinical 
effects are mainly due to more complex mechanisms 
than simple leucocyte contamination. 
TRALI is a syndrome characterised by acute 
respiratory distress and its classical and fulminant 
presentation is indistinguishable from adult respiratory 
distress syndrome, secondary to other causes such 
as toxic inhalation, sepsis or aspiration. It is a severe 
transfusion reaction characterised by non-cardiogenic 
lung oedema, hypoxaemia and respiratory distress 
occurring about 6 hours after blood transfusion. The 
incidence of TRALI differs greatly in retrospective 
and prospective studies; in some countries there is also 
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Table I - Efficacy of different filters in preventing prion infections. 
Author, year of 
publication
Type of blood Type of infection Type of filter Effect on prion transmission
Gregori, 200492 Pooled hamster blood Scrapie-infected Whole blood filter
Leucotrap WB collection set (Haemonetics/
Pall)
Reduced: 
−42% of the initial infectivity






LR-RBC: 2-15% of WB values







Reduced for all filters. 
Significant for:
Pall Day 0 (p<0.001)







Amicus gave significantly higher values 
than all other groups (ANOVA p<0.0001) 
and the Autostop significantly lower 
(p=0.04). The levels of supernatant 
PrPc were also significantly different 
(ANOVA p<0.0001), with the Autostop 
and the MCS showing lower values than 













Sheep blood PrPSc RBC filter 
T3953 
PRP filter 
Fresenius/NPBI CompoStop F730 
Not modified*
LaCroux, 201296 Sheep blood PrPSc RBC filter
ASAHI KASEI combination filter
Pall Medical Leucotrap Affinity Plus
Reduced**
(still present in lymphoid tissue and 
central nervous system)
Cardone, 2014101 Human blood Scrapie-infected 
hamster brain





















Brain homogenates Macaque P-Capt (prion removal after 
leucoreduction)
Prototype PMC#005 (simultaneous 
leucoreduction and prion removal)
No sign of infection 
Infection in one animal
Effect on prion transmission is expressed in percentage or logarithm. §Filtration was carried out under two conditions: (i) ambient temperature on the day of collection (day 0) and 
(ii) after holding at 4 °C overnight (day 1).§§ Filters were suitable only for condition (ii). #Only the MCS+ required WBC filtration (LRF6H filter, Pall Biomedical); the Spectra 
LRS and Amicus used fluidised particle bed and elutriation, respectively, to achieve leucoreduction. The concentrations of total PrPc antigen, expressed as units of PrPc per mL, 
were measured in all samples. Reduction, if present, is expressed as a percentage. For platelets, because the manufacturing methods used did not allow a direct comparison of 
products before and after filtration, a grouped study design was used for whole blood-derived platelets to enable a direct comparison of different filtered products with unfiltered 
product from the same pool and an ungrouped comparison with apheresis platelets. *In this study, sheep blood components had the same specifications as those for human blood 
using similar processing methods and commercially available blood packs and leucoreduction filters. Whole blood has shown the highest rate of transmission (37.5% of recipients 
infected), followed by buffy coat (32.4%), platelets (24.3%), then red cells (18.9%) and plasma (13.2%). **In this study, leucoreduction filters and filters combining leucoreduction 
and the capture of non-leucocyte associated prion infectivity are evaluated. In this table, RBC filters (ASAHI KASEI and Pall) are both combined filters for leucoreduction and 
prion depletion. Systematic detection of abnormal PrP (using both immunohistochemistry and western-blot analysis) in lymphoid tissues and central nervous system was carried 
out in recipients. The reduction was evaluated 400 days after inoculation. *** Whole blood and RBC were leucoreduced by commercial filters (WBF3 for blood and BPF4 for 
RBC, Pall Corporation), divided in two identical aliquots, and finally filtered through either LAPRF1 orLAPRF2 filters (Leukotrap, Pall Corporation). Effect on prion transmission 
is expressed as removal factor (RF), calculated as log titer of prefiltered samples minus log titer after filtration.
WB: whole blood; PrPSc: prion protein; RBC: red blood cell; PRP: platelet-rich plasma; LR-RBC: leucoreduced-red blood cell; LR-FFP: leucoreduced-fresh frozen plasma. 
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a tendency to under-diagnosis and underreporting of 
this syndrome103. Overall, its incidence is estimated to 
range between 0.08% and 15% of patients receiving a 
blood transfusion. According to the two-hit hypothesis, 
the capillary leak causing TRALI results from two 
succeeding events: the adhesion of primed neutrophils to 
pulmonary endothelial cells (first hit) and the subsequent 
activation of both cells by antibodies or inflammatory 
mediators present in transfused blood (second hit)104-106. 
The pathogenesis of TRALI involves both antibody-
mediated and antibody-negative mechanisms and several 
transfusion-related and recipient-related risk factors 
variably interact in each case in triggering the syndrome. 
Massive transfusion, mechanical ventilation, sepsis, 
haematological malignancies, end-stage liver disease 
and cardiac surgery are all acknowledged important 
risk factors for TRALI. It is not, therefore, surprising 
that the patients mainly involved are those who are 
critically ill104-114. 
Universal LR has been associated, on the one hand115, 
with a decreased incidence of acute respiratory distress 
syndrome in a cohort of critically ill patients and, on the 
other hand116, with no reduction of lung injury. In 2010, 
Blumberg et al.117 showed a statistically significant, 83% 
reduction of the rate of TRALI from 2.8 to 0.48 cases 
per 100,000 components transfused (p=0.01) before 
and after universal LR, respectively. Interestingly, LR 
is also associated with a reduction of accumulation of 
lysophosphatidylcholines, which have been implicated 
in the onset of TRALI118. Recently, Silliman et al. showed 
that prestorage filtration may reduce pro-inflammatory 
activity in the RBC supernatant and prevent TRALI119. 
They demonstrated that the experimental filters 
developed for small-volume filtration removed more 
than 96% of IgG, 93% of antibodies to HLA class I 
antigens, and 99% of antibodies to HLA class II antigens. 
In addition, such removal of antibodies inhibited acute 
lung injury in a two-event, in vivo, animal model of 
TRALI thus supporting the efficacy of LR in preventing 
TRALI in an experimental model.
In addition, some recent studies confirmed that 
residual leucocytes and platelets are a stressful storage 
factor in stored RBC, especially if non-leucoreduced. 
LR may have a positive effect on some RBC 
senescence phenomena such as haemolysis, irreversible 
echinocytosis, microvesiculation, accumulation of 
reactive oxygen species/calcium, band 3-related 
senescence modifications, and membrane proteome 
stress biomarkers119-122.
TA-GVHD may occur in immunocompromised 
patients such as transplant recipients, onco-
haematological patients, foetuses or premature infants. 
It may also develop in immunocompetent transfusion 
recipients who are heterozygous for an HLA haplotype 
for which the donor is homozygous123. As TA-GVHD is 
correlated to exposure to allogeneic donor leucocytes, 
it might be useful to reduce leucocytes in blood 
components. However, it is not possible to advocate 
LR to prevent TA-GVHD because this disease also 
occurs in patients transfused with leucoreduced blood 
components124. 
In conclusion, the prevention of TRALI is based 
on the exclusion from clinical use of high-plasma 
volume blood components donated by multiparous 
and/or transfused donors, as well as donors involved 
in TRALI cases or with proven antibodies to HLA 
or human neutrophil antigens. As far as concerns the 
prevention of TA-GVHD, leucocyte inactivation and 
gamma-irradiation have proven efficacy125. LR does not 
have an evidence-based role in the prevention of TRALI 
and TA-GVHD.
Evaluation of costs
As mentioned above, LR prevents some transfusion 
reactions but analyses on its cost-effectiveness are 
scarce and mainly based on observational data, as 
only a limited number of RCT on this issue have been 
carried out. In Canada, the introduction of universal LR 
caused reductions in the mortality rate126 and the rate of 
alloimmunisation against HLA antigens127. In Germany, 
universal LR gave a substantial contribution to reducing 
bacterial contamination of blood components128. 
Contrariwise, in Spain universal LR is not encouraged 
and costs from LR are considered excessive, when 
compared with the clinical benefits129. 
Cost-effectiveness was analysed in a RCT in 
patients undergoing cardiac valve surgery. In this trial, 
the use of leucoreduced blood components saved 214 
US$ per patient, when more than four RBC units were 
transfused130. Clinical outcomes such as mortality, 
duration of hospitalisation, infections and development 
of multi-organ failure were assessed. Two additional 
RCT published in the Netherlands showed that LR was 
cost-effective: the benefit of LR of RBC ranged between 
220 USD and 310 USD per life-year gained in patients 
undergoing coronary artery bypass grafting131,132.
The costs of LR were also evaluated in another 
RCT performed in the USA133. In this trial, which was 
carried out in a general hospital excluding patients 
with established medical indications for leucoreduced 
blood components, the primary outcomes such as in-
hospital death, duration of hospitalisation from first 
transfusion event, and total hospitalisation costs were not 
statistically significantly different (p=0.64, p=0.21, and 
p=0.24, respectively) between patients and controls. No 
additional costs were associated with LR but there were no 
clinical benefits either. Recently, Tsantes et al.134 showed 
that LR did not have a favourable cost-effectiveness ratio 
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in preventing FNHTR. They analysed more than 80,000 
RBC transfusions, of which 63% were leucoreduced: the 
calculated incremental cost-effectiveness ratio (ICER) 
was € 6,916, which is the cost of preventing one FNHTR. 
In conclusion, although the cost-effectiveness 
remains controversial, as cost-effectiveness analyses 
relate the costs of a programme/technique to its key 
outcomes or benefits, we deem that health technology 
assessment should include all the aforementioned 
potential advantages of LR (in unselected populations 
of patients) in the projected benefits. This approach 
would probably provide sufficient evidence to support 
a recommendation aiming at including this policy in the 
current standard of care.
Conclusions
From the analysis of the available information, it 
seems fair to conclude that LR can be recommended 
for the prevention of HLA and HPA immunisation 
and platelet refractoriness. In addition, WBC-depleted 
platelets should be used as equivalent products to 
apheresis platelets. The current available literature 
data provides robust evidence supporting an equivalent 
role of CMV-seronegative and leucodepleted blood 
components in preventing the risk of CMV transfusion 
transmission. A consistent wealth of observational 
data shows that LR is effective in reducing the rate 
of FNHTR. LR is also effective in reducing post-
operative infections and mortality in cardiac surgery 
patients and can play a key role in the prevention of 
transfusion-transmitted EBV and HTLV infections. 
Finally, experimental data from animal studies 
exploiting affinity prion reduction filters provide very 
promising results for the prevention of transfusion-
transmitted vCJD.
On these bases, several European countries135, as 
well as Canada, introduced universal LR about 10 
years ago. Current evidence on a poor cost/benefit of 
LR is widely disputable, as it does not include balanced 
evaluations encompassing the extensive list of its proven 
and probable benefits136. 
The Authors declare no conflict of interest.
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